SK Bioscience
SK Bioscience invests $85M on a 7% share in the vaccine manufacturer, Novavax, to keep it afloat
SG Tylor
Following its setback during the pandemic phase of COVID-19 with a delayed vaccine, Novavax is now aiming for recovery in ...
Following its setback during the pandemic phase of COVID-19 with a delayed vaccine, Novavax is now aiming for recovery in ...